These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 23361084)

  • 21. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
    Deodhar A; Helliwell PS; Boehncke WH; Kollmeier AP; Hsia EC; Subramanian RA; Xu XL; Sheng S; Agarwal P; Zhou B; Zhuang Y; Ritchlin CT;
    Lancet; 2020 Apr; 395(10230):1115-1125. PubMed ID: 32178765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.
    Deodhar A; Gottlieb AB; Boehncke WH; Dong B; Wang Y; Zhuang Y; Barchuk W; Xu XL; Hsia EC;
    Lancet; 2018 Jun; 391(10136):2213-2224. PubMed ID: 29893222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study.
    Blanco FJ; Möricke R; Dokoupilova E; Codding C; Neal J; Andersson M; Rohrer S; Richards H
    Arthritis Rheumatol; 2017 Jun; 69(6):1144-1153. PubMed ID: 28217871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE.
    D'Agostino MA; Schett G; López-Rdz A; Šenolt L; Fazekas K; Burgos-Vargas R; Maldonado-Cocco J; Naredo E; Carron P; Duggan AM; Goyanka P; Boers M; Gaillez C
    Rheumatology (Oxford); 2022 May; 61(5):1867-1876. PubMed ID: 34528079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
    Merola JF; Landewé R; McInnes IB; Mease PJ; Ritchlin CT; Tanaka Y; Asahina A; Behrens F; Gladman DD; Gossec L; Gottlieb AB; Thaçi D; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Coates LC
    Lancet; 2023 Jan; 401(10370):38-48. PubMed ID: 36495881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
    Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    McInnes IB; Asahina A; Coates LC; Landewé R; Merola JF; Ritchlin CT; Tanaka Y; Gossec L; Gottlieb AB; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Mease PJ
    Lancet; 2023 Jan; 401(10370):25-37. PubMed ID: 36493791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis.
    Dokoupilová E; Aelion J; Takeuchi T; Malavolta N; Sfikakis PP; Wang Y; Rohrer S; Richards HB
    Scand J Rheumatol; 2018 Jul; 47(4):276-281. PubMed ID: 29458278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
    Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
    Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    Arthritis Rheumatol; 2017 Nov; 69(11):2151-2161. PubMed ID: 28805045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
    Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
    Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
    Hueber W; Sands BE; Lewitzky S; Vandemeulebroecke M; Reinisch W; Higgins PD; Wehkamp J; Feagan BG; Yao MD; Karczewski M; Karczewski J; Pezous N; Bek S; Bruin G; Mellgard B; Berger C; Londei M; Bertolino AP; Tougas G; Travis SP;
    Gut; 2012 Dec; 61(12):1693-700. PubMed ID: 22595313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
    Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study.
    Kavanaugh A; McInnes IB; Mease PJ; Hall S; Chinoy H; Kivitz AJ; Wang Z; Mpofu S
    J Rheumatol; 2016 Sep; 43(9):1713-7. PubMed ID: 27307536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension.
    D'Agostino MA; Carron P; Gaillez C; Conaghan PG; Naredo E; López-Rdz A; Šenolt L; Burgos-Vargas R; Hanova P; Padovano I; Cazenave T; Stoenoiu MS; Backhaus M; Mouterde G; Bao W; Goyanka P; Boers M; Schett G
    Semin Arthritis Rheum; 2023 Dec; 63():152259. PubMed ID: 37660536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
    Nakagawa H; Niiro H; Ootaki K;
    J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
    Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
    J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
    McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
    Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.